Cargando…
Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
Background: Despite offering an attractive option, the role of allogeneic stem cell transplantation (alloSCT) for treatment of multiple myeloma (MM) remains unclear. Methods: Recognizing the paucity of data in the Asian population, we retrospectively evaluated the outcomes of 24 patients (median age...
Autores principales: | Park, Hyunkyung, Byun, Ja Min, Yoon, Sung-Soo, Koh, Youngil, Shin, Dong-Yeop, Hong, Junshik, Kim, Inho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466005/ https://www.ncbi.nlm.nih.gov/pubmed/32717932 http://dx.doi.org/10.3390/jcm9082354 |
Ejemplares similares
-
Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023) -
Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin
por: Seo, Jeongmin, et al.
Publicado: (2021) -
Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis
por: Kim, Dong Hyun, et al.
Publicado: (2022) -
P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
por: Min Byun, Ja, et al.
Publicado: (2023) -
Should patients receive consolidation chemotherapy before reduced
intensity allogeneic hematopoietic stem cell transplantation for acute myeloid
leukemia in first complete remission?
por: Byun, Ja Min, et al.
Publicado: (2021)